Budget Impact and Affordability

Why this matters in health economics

Cost-effectiveness answers one question — is this a good use of money per person treated? — and budget impact answers a different one: can we pay for it across everyone who is eligible, out of the money we actually hold, in the years the bill falls due? A director who confuses the two will approve something the organization cannot fund, or reject something it could have afforded, and either mistake costs patients care. The two analyses are complementary, not rival, and a mature decision uses both (cost-effectiveness itself belongs to Chapter 2.1 — Economic Evaluation, which this chapter assumes rather than repeats).

The stakes are most visible when a highly cost-effective technology arrives for a large population. The clearest modern case is the arrival of a curative treatment for chronic hepatitis C: a therapy that was, per patient, outstanding value — a genuine cure replacing decades of managing liver disease — yet whose total cost, multiplied across every infected person, exceeded what payers could release in a single year. Systems worldwide responded not by disputing the value but by restricting who could be treated first. The drug was worth it and unaffordable at the same time, and that paradox is the subject of this chapter.

For a busy leader, budget impact is where health economics meets the cash flow statement. A finance director does not spend quality-adjusted life years; they spend a capped budget, in-year, against competing claims from every service. Ignoring budget impact turns a sound evaluation into an unfunded promise — a commitment that either blows the budget, triggers an emergency raid on other services, or quietly fails to reach the patients it was approved for. Getting it right lets an organization say yes deliberately, plan the cash, and stage the roll-out so the promise is real.

Core concepts

A budget impact analysis (BIA) estimates the financial consequences of adopting a new intervention for a specific budget holder over a short, decision-relevant horizon — typically one to five years. Its output is not a ratio but a stream of numbers: the expected change in total spending, year by year, if the intervention is introduced. Where cost-effectiveness compares the marginal cost and benefit of one more patient, budget impact aggregates across the whole eligible population and asks what the payer's outlay becomes. The two answer to different masters — the cost-effectiveness analysis to the value of a treatment, the BIA to the size of the cheque — and the good-practice guidance treats them as separate, mandatory companions.

The distinction rests on a simple arithmetic that decision-makers routinely underestimate. A quality-adjusted life year gained at a modest cost per patient can still translate into an enormous total when the eligible population is large. Cost-effectiveness is a per-unit verdict; affordability is that unit multiplied by volume. A drug can sit comfortably below a payer's cost-per-QALY threshold and still, at population scale, demand more cash in year one than the entire budget can bear. This is the affordability-versus-value distinction, and it is why a favourable incremental cost-effectiveness ratio is a necessary but not sufficient condition for funding.

The reason the total bites is opportunity cost at scale. In a fixed budget, money committed to a new intervention across a whole population must come from somewhere — services delayed, expansions cancelled, or care displaced elsewhere. The opportunity cost of a single cost-effective treatment is small and often notional; the opportunity cost of adopting it for everyone eligible, at once, is concrete and large enough to be felt across the system. Budget impact is the tool that sizes that displacement before it happens, rather than discovering it afterwards in an overspend (the mechanisms for releasing money and setting priorities in response belong to Chapter 3.3 — Rationing).

Financial headroom is the space a budget holder actually has to absorb new spending — the gap between committed costs and available funds, plus whatever can realistically be released from lower-value activity. Headroom is almost always far smaller than the total budget, because most of it is already spoken for. A new commitment that fits within headroom is affordable; one that exceeds it requires either new money, disinvestment, or a slower path to full adoption. Naming the headroom honestly is what separates a fundable decision from a wish.

When a valuable intervention exceeds available headroom, the disciplined response is phased or managed adoption: introducing it in stages rather than all at once. Staging can prioritize the patients who benefit most first, cap the numbers treated per year, spread the cash across several budget cycles, or pair adoption with a commercial arrangement that smooths the payer's exposure. This is where budget impact connects to the commercial tools of Chapter 2.4 — Pharmacoeconomics, whose managed entry agreements exist precisely to reconcile value with affordability. Phased adoption is not a refusal to fund; it is a plan to fund something real within the money that exists.

Two further ideas frame the analysis. First, the time horizon and discounting: because a BIA is short-run and about cash flow, it is usually presented in undiscounted, nominal terms so a finance function can reconcile it to real budgets, unlike the long-horizon, discounting-based lifetime view of a cost-effectiveness model. Second, the cost of delay: staging or restricting adoption to fit headroom carries its own price in health forgone by patients who wait, and an honest analysis names that cost rather than hiding it behind the budget line. A health technology assessment that reports value without affordability, or affordability without value, has done only half the job.

Best practices

1. Run budget impact and cost-effectiveness as two separate analyses, and require both. They answer different questions and must not be collapsed into one. A favourable cost-per-QALY tells a payer the intervention is worth having; a budget impact analysis tells them whether they can pay for it this year and next. Present them side by side, and never let a strong value case substitute for an affordability case, or vice versa — a cheap, low-value intervention for a huge population can be more of a budget threat than an expensive, high-value one for a handful of patients.

2. Size the eligible population from the payer's real denominator, not the trial's. The single largest driver of budget impact is how many people will actually be treated, and this is where analyses go most wrong. Start from the payer's covered population, apply realistic prevalence and incidence, then subtract those who are undiagnosed, contraindicated, already treated, or who will decline. A model that assumes every theoretically eligible patient is treated in year one overstates the bill and provokes a reflexive no; one that assumes unrealistically slow uptake understates it and sets up an overspend.

3. Model uptake as a curve over time, not a switch. New interventions diffuse gradually — constrained by diagnosis rates, clinician confidence, capacity, and patient demand — so budget impact typically ramps across the horizon rather than landing fully in year one. Build an explicit uptake trajectory for each year, justify it from comparable historical roll-outs where you can, and make it a headline variable. The shape of the curve often matters more to affordability than the unit price, because it decides how much of the total bill falls in the tightest budget year.

4. Count what the new intervention displaces, not just what it adds. Budget impact is a net figure: the cost of the new pathway minus the cost of the care it replaces. A treatment that averts hospital admissions, cures a chronic condition, or removes an existing drug from the pathway releases money that offsets its own cost. Identify these offsets explicitly and be realistic about their timing — savings that arrive in year five do nothing for a year-one cash constraint, and cashable savings (a ward you can actually close) differ from notional ones (a bed-day freed but still staffed).

5. State the financial headroom explicitly, and whose budget it is. An affordability judgement is meaningless without naming the budget it is judged against and how much room that budget has. Identify the specific budget holder, the horizon over which they must find the money, and the realistic headroom after existing commitments. The same intervention can be affordable to a national payer and ruinous to a single hospital, so always attach the analysis to a named budget and a named holder rather than to "the system" in the abstract.

6. Test the affordability conclusion against uptake, price, and population, because these swing it hardest. A budget impact analysis is a projection built on uncertain volumes, so its conclusion must be stress-tested. Vary the eligible population, the uptake curve, the net price after any confidential discount, and the offsets, and report how the year-by-year spend moves. A result that stays affordable only if uptake is slow and every offset materializes on schedule is a fragile basis for a commitment, and decision-makers deserve to see that fragility before they sign.

7. When value exceeds headroom, design a phased adoption plan rather than defaulting to yes or no. A binary choice between full immediate funding and outright rejection wastes the middle ground where most good decisions live. If an intervention is cost-effective but unaffordable at once, stage it: prioritize the highest-need subgroup, cap annual volumes, or spread introduction across budget cycles so the cash matches the headroom. Make the staging criteria explicit and clinically defensible, and publish the pathway to fuller access, so restriction reads as a funded plan rather than a covert denial.

8. Name the cost of delay that phasing imposes, and who bears it. Staging or restricting adoption to fit a budget is not free — patients who wait may deteriorate, and the health they lose is a real cost of the affordability constraint. An honest analysis quantifies or at least describes that forgone health and identifies who carries it, because the group deprioritized for budget reasons is often the one with the weakest voice. Pairing every phasing decision with its human cost keeps the trade-off visible and guards against dressing up health care rationing as prudence (the fairness of that process is developed in Chapter 3.3 — Rationing).

9. Use commercial and financial mechanisms to reconcile value with affordability. When the obstacle is cash flow rather than value, the answer may be a deal rather than a refusal. Volume caps, price-volume agreements, phased payment, outcome-based arrangements, and confidential discounts can bring a high-value intervention within headroom without denying it to patients. These managed entry agreements are the subject of Chapter 2.4 — Pharmacoeconomics; the budget-impact contribution is to quantify precisely how much smoothing is needed and over what horizon, so the negotiation targets a real number.

10. Reconcile the budget impact model to the payer's actual accounts. A BIA that cannot be traced back to real budget lines will not survive contact with a finance function. Present it in the payer's currency, price year, and nominal terms; align its cost categories to how the organization actually books spending; and separate cashable savings from notional ones. The goal is a document a director of finance can lift straight into a budget-setting round, not an academic model that has to be re-derived before anyone can act on it.

11. Flag the equity consequences of both adoption and restriction. Affordability decisions redistribute care. Funding a costly intervention for one condition displaces spending that may have served more disadvantaged groups elsewhere, while restricting a valuable intervention to a priority subgroup decides who waits. Report who gains and who is deprioritized under each option, so the board sees the distributional pattern rather than only the aggregate cash line (developed in Chapter 3.4 — Equity).

12. Follow a recognized good-practice standard so the analysis is credible and comparable. Budget impact analysis has an established methodology — most prominently the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) good-practice guidance — covering the population framing, the time horizon, the treatment of offsets, and the presentation of results. Following a named standard makes the analysis auditable, resistant to gaming, and comparable across submissions, which matters most when the party supplying the model also benefits from a favourable answer.

Questions to discuss with your team

1. How many people will we actually treat, in each of the next few years, and how confident are we in that number? The eligible population and its uptake curve drive budget impact more than any other input, yet they are the softest numbers in the analysis. The tension is that the party proposing the intervention has an incentive to quote a large clinical need (to argue importance) while assuming modest uptake (to keep the bill low), and those two assumptions can quietly contradict each other. A good discussion pins down the real denominator — covered population, diagnosed, eligible, willing, and able to access — and builds an explicit year-by-year trajectory rather than a single figure. It should also ask what happens if uptake runs faster than assumed, because optimistic diffusion is the most common way an affordable-looking commitment becomes an overspend. An honest answer states the volume range, names the evidence behind the curve, and identifies the budget year in which the bill peaks.

2. Whose budget pays for this, over what horizon, and how much room does that budget really have? Affordability is always relative to a specific pot of money held by a specific person, yet decisions are often debated as if "the system" would pay. This question forces the team to name the budget holder, the years over which they must find the cash, and the genuine headroom after existing commitments — which is almost always far smaller than the headline budget. The deeper tension is that the intervention may be affordable to a national payer but crippling to the local provider expected to deliver it, or the savings may accrue to a different budget from the one bearing the cost. An honest answer identifies where the money comes from, distinguishes cashable release from notional savings, and is candid about whether funding this means new money, disinvestment, or a slower roll-out.

3. If this is genuinely good value but we cannot afford it all at once, how should we phase it — and who waits? The most consequential affordability decisions are rarely yes or no; they are about sequence and pace. This question surfaces the criteria for deciding who is treated first when everyone eligible cannot be treated immediately: greatest clinical need, greatest capacity to benefit, or greatest cost offset. The tension is that any staging rule advantages some patients over others, and the group deprioritized for budgetary reasons often has the least power to object, so a rule chosen for administrative convenience can quietly become an equity failure. A good discussion also weighs the cost of delay — the health lost by those who wait — against the budget relief that phasing buys. An honest answer sets explicit, clinically defensible staging criteria, publishes the path to fuller access, and names the human cost of the wait rather than letting the budget line speak for it.

4. Which of the savings we are counting are real cash we can release this year, and which are merely notional? A budget impact figure is a net number, so the offsets we claim decide whether the intervention looks affordable — yet offsets are where wishful thinking creeps in. The tension is between two kinds of saving that finance treats very differently: a cashable release, such as a ward you can actually close or a drug you can stop buying, genuinely frees money, while a notional saving, such as a freed bed-day on a ward that stays open and staffed, relieves pressure without releasing a penny. There is also a timing trap, because savings that arrive in year five do nothing for a year-one cash constraint even when they are real. A good discussion interrogates each claimed offset for its cashability and its year of arrival, and asks whether the budget that bears the cost is the same one that receives the saving. An honest answer separates cashable from notional savings, matches each to the budget year that actually needs relief, and resists booking tomorrow's avoided admissions against today's bill.

5. What commercial or financial mechanism could bring this within our headroom without denying it to patients? When the obstacle is cash flow rather than value, refusal is a failure of imagination, because a deal can often reconcile the two. This question moves the team from a binary verdict to a design problem: a volume cap, a price-volume agreement, phased payment, or an outcome-based arrangement can each smooth the payer's exposure while still reaching patients. The tension is that these instruments shift risk and administrative burden — a confidential discount obscures the true price for future comparisons, an outcome-based deal demands data the system may not collect well, and a volume cap can turn into a covert queue. A good discussion quantifies precisely how much smoothing is needed and over what horizon, so the negotiation targets a real number rather than a vague hope of a discount. An honest answer names the specific mechanism, states what it costs to administer and monitor, and confirms it brings the year-by-year spend inside genuine headroom rather than merely relabelling the problem (the design of these arrangements belongs to Chapter 2.4 — Pharmacoeconomics).

6. Who gains and who is displaced across the whole budget if we say yes to this, alongside everything else competing for the same money? Affordability is never judged on one technology in isolation; it is judged against a pipeline of claims on a fixed pot, and funding this one reshapes what everyone else receives. This question forces a portfolio view: several interventions may each be cost-effective, yet together they exceed the headroom, so a yes here is an implicit no somewhere the board may not be looking. The tension is distributional — the money to fund a costly intervention for one condition is displaced from services that may have served more disadvantaged groups, while restricting it to a priority subgroup decides who waits, and both patterns can widen inequity. A good discussion reports the gainers and the displaced under each option, not just the aggregate cash line, and checks whether the displacement falls on those least able to bear it. An honest answer makes the whole-budget trade-off visible, names the losers as well as the winners, and accepts that the fairness of that pattern is a decision to be owned rather than an accident of the spreadsheet (developed in Chapter 3.4 — Equity and Chapter 3.3 — Rationing).

In practice: a health economics example

The National Health Insurance Fund of Marisar, a fictional upper-middle-income country in Southeast Asia, is deciding whether to cover a new once-weekly injectable medicine for obesity and its metabolic complications. The clinical evidence is strong, and the Fund's health technology assessment unit has already found the drug cost-effective per patient by the Fund's own cost-per-QALY reference case: it produces meaningful, durable weight loss and reduces downstream diabetes and cardiovascular events. On value, the answer is yes. The board's finance committee, however, has asked a different question — what happens to the Fund's cash if it says yes to everyone who qualifies?

The Fund's analysts build a budget impact analysis separate from the cost-effectiveness model. They start from the covered population and work down to a realistic treated denominator: the large number of members with obesity, minus those without the metabolic complications that define eligibility, minus the undiagnosed, minus those who will not seek or tolerate treatment. Even after these reductions the eligible group is very large, because obesity is common — and this is the crux. At the drug's net price after the confidential discount already negotiated, treating the full eligible population in the first year would consume a share of the Fund's annual budget far beyond any plausible headroom, dwarfing the sums involved in most previous coverage decisions. The per-patient value never changed; the volume is what breaks the budget.

The analysts model uptake as a curve rather than a switch, and count offsets honestly. Some diabetes and cardiovascular costs are avoided, but most of those savings arrive years later and few are cashable in the near term, so they do little to relieve the year-one constraint. Sensitivity analysis confirms the affordability conclusion is driven overwhelmingly by the eligible population and the speed of uptake: even halving assumed first-year uptake leaves the net cost above the Fund's headroom. This mirrors the pattern the world learned from the arrival of curative hepatitis C therapy — a treatment of undisputed value whose sheer aggregate cost forced payers everywhere to stage access rather than treat all at once.

So the analysts reframe the recommendation from "fund or reject" to "how to phase". They propose managed adoption: cover the medicine first for members at highest cardiovascular risk, where the capacity to benefit and the cost offsets are greatest, with an explicit annual volume cap set to the Fund's headroom and a published pathway to widen eligibility as budget allows and as long-term savings materialize. They pair this with a price-volume agreement negotiated under the tools of Chapter 2.4 — Pharmacoeconomics, so that unit price falls as volume rises. Crucially, they name the cost of delay — the members with obesity but lower cardiovascular risk who will wait, and the health they may lose meanwhile — and flag the equity question of who is deprioritized, so the board decides the sequence with open eyes (the fairness of that rationing process is the province of Chapter 3.3 — Rationing). The Fund funds the drug, but as a staged, capped, affordable programme rather than an open-ended commitment it could not have honoured.

Four sector lenses

Startup

A digital health or biotech start-up usually encounters budget impact as the second hurdle after cost-effectiveness, and often the one it is least prepared for. Founders instinctively argue value per patient and are surprised when a payer, convinced of the value, still declines because the aggregate cost across the covered population is unaffordable in-year. The pragmatic move is to build a credible budget impact analysis early, with a realistic treated denominator and an honest uptake curve, and to arrive with an affordability proposal — a volume cap, a phased launch, a price-volume offer — rather than only a value story. A start-up that helps a payer manage the cash, not just believe the science, is far more likely to be adopted.

Small business

An established small provider — a group practice, a single clinic, a diagnostics lab, or a niche device supplier — meets budget impact from the buyer's side of the desk, against its own fixed and largely committed budget. Unlike a start-up chasing a payer's decision, its problem is steady-state: whether adopting a new drug, test, or piece of equipment fits the modest headroom left after payroll, premises, and existing contracts, and whether the reimbursement it receives actually covers the in-year cash outlay. Timing bites harder at this scale, because a small balance sheet cannot absorb a large upfront cost while waiting for downstream savings or slow reimbursement to catch up. The disciplined move is to size the real annual cost against genuine headroom, negotiate payment terms or volume-based pricing with the supplier, and stage adoption to match cash flow rather than committing to full roll-out at once. A practice that treats affordability as a cash-flow question, not just a value one, avoids the overcommitment that can sink a small operation.

Enterprise

A large provider, insurer, or payer organization runs budget impact as a standing part of its formulary and investment decisions, integrated with financial planning rather than bolted on. The questions are portfolio-scale: several high-cost technologies may each be cost-effective, yet together they exceed the headroom, forcing a sequencing decision across the whole pipeline. The enterprise discipline is a consistent BIA method, a clear view of headroom across budget cycles, and an explicit link between adoption decisions and where the offsetting money will come from — including the harder work of disinvestment. Enterprises that do this well treat affordability as a governed, cross-year planning function, not a series of one-off shocks.

Government

A ministry or national payer carries budget impact as an instrument of fiscal accountability for the whole population, and its affordability decisions are politically exposed in a way a firm's are not. When a valuable, high-budget-impact technology arrives, government must reconcile statutory duties to fund effective care with a finite, often legally capped budget, and defend the resulting phasing to patients, clinicians, industry, and the treasury. Some systems have made this explicit: England's National Institute for Health and Care Excellence, for instance, operates a budget impact test that triggers commercial negotiation when a technology's projected annual cost to the National Health Service crosses a defined level, precisely so that affordability is managed openly rather than through a silent funding failure. Government's task is to make the affordability trade-off transparent and procedurally fair, because the alternative — an unfunded mandate — damages both patients and public trust.

Common failure modes

• Treating cost-effectiveness as proof of affordability. Approving a technology because its cost-per-QALY is favourable, without asking what the total costs across the whole eligible population. Fix: require a separate budget impact analysis for every significant funding decision, and judge affordability against named headroom.

• Inflating or lowballing the eligible population. Assuming everyone theoretically eligible is treated at once (a reflexive no), or assuming implausibly slow uptake (a future overspend). Fix: build the denominator from the payer's real covered population and model an explicit, justified uptake curve.

• Booking savings that never become cash. Offsetting the cost with downstream savings that arrive years later or that free a resource without releasing money. Fix: separate cashable from notional savings, respect their timing, and match them to the budget year that actually needs relief.

• Ignoring whose budget pays. Concluding an intervention is affordable "to the system" while the cost falls on a local budget with no headroom, or the savings accrue to a different pot. Fix: attach the analysis to a named budget holder and horizon, and check that cost and offset land in the same place.

• Defaulting to a binary yes or no. Treating an unaffordable-but-valuable intervention as a rejection, wasting the phased middle ground. Fix: design a managed adoption plan — prioritized subgroup, volume cap, phased payment — with published criteria and a path to wider access.

• Hiding the cost of delay. Presenting phasing or restriction as pure prudence while staying silent on the health lost by those who wait. Fix: name the forgone health and who bears it, so restriction is an accountable decision rather than a covert denial.

Maturity model

Checklist

• Produce a budget impact analysis separately from the cost-effectiveness analysis, and require both before deciding.
• Build the eligible population from the payer's covered denominator, subtracting undiagnosed, contraindicated, already-treated, and declining patients.
• Model uptake as an explicit year-by-year curve, and make it a headline, stress-tested variable.
• Report net budget impact, counting displaced costs and offsets, and respect the timing of any savings.
• Name the specific budget holder, the horizon, and the realistic headroom the spend is judged against.
• Separate cashable savings from notional ones, and check cost and offset fall on the same budget.
• Test the affordability conclusion against uptake, net price, population, and offsets.
• Where value exceeds headroom, design a phased adoption plan with explicit, clinically defensible staging criteria and a published path to wider access.
• Name the cost of delay that phasing imposes and identify who bears it.
• Use commercial mechanisms (volume caps, price-volume or outcome-based deals) to bring value within headroom, and quantify how much smoothing is needed.
• Present the analysis in the payer's currency, price year, and nominal terms, reconciled to real budget lines.
• Follow a recognized good-practice standard (e.g. ISPOR) so the analysis is auditable and comparable.

Key sources

• ISPOR (International Society for Pharmacoeconomics and Outcomes Research) — Principles of Good Practice for Budget Impact Analysis (Task Force reports, Mauskopf et al. 2007 and Sullivan et al. 2014, published in Value in Health) — the standard methodological reference for budget impact analysis.
• NICE (National Institute for Health and Care Excellence) — the budget impact test and health technology evaluation methods, as a national exemplar of managing affordability alongside value — https://www.nice.org.uk/process/pmg36
• WHO (World Health Organization) — health financing and health technology assessment publications on affordability and priority-setting in health systems worldwide.
• Office of Health Economics and national HTA bodies (IQWiG in Germany, CADTH/CDA in Canada, PBAC in Australia, ICER in the United States) — practice on managing high-budget-impact technologies.
• The chronic hepatitis C direct-acting antiviral experience — widely documented internationally as the canonical case of a highly cost-effective cure whose aggregate budget impact forced staged access.

References

1. Pharmacoeconomics — Wikipedia — https://en.wikipedia.org/wiki/Pharmacoeconomics
2. Cost-effectiveness analysis — Wikipedia — https://en.wikipedia.org/wiki/Cost-effectiveness_analysis
3. Quality-adjusted life year — Wikipedia — https://en.wikipedia.org/wiki/Quality-adjusted_life_year
4. Opportunity cost — Wikipedia — https://en.wikipedia.org/wiki/Opportunity_cost
5. Discounting — Wikipedia — https://en.wikipedia.org/wiki/Discounting
6. Cost of delay — Wikipedia — https://en.wikipedia.org/wiki/Cost_of_delay
7. Health technology assessment — Wikipedia — https://en.wikipedia.org/wiki/Health_technology_assessment
8. Hepatitis C — Wikipedia — https://en.wikipedia.org/wiki/Hepatitis_C
9. Health care rationing — Wikipedia — https://en.wikipedia.org/wiki/Health_care_rationing
10. ISPOR — Budget Impact Analysis good-practice Task Force reports (Value in Health) — International Society for Pharmacoeconomics and Outcomes Research — https://www.ispor.org
11. NICE — Health technology evaluations: the manual (PMG36), including the budget impact test — National Institute for Health and Care Excellence — https://www.nice.org.uk/process/pmg36